Skip to main content
SpringerLink
Log in

Prevention and Pharmacovigilance

What Should We Do, What Can We Do?

  • Editorial
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mease M. Measuring REMS effectiveness: time for a program overhaul? [abstract]. Drug Saf 2011; 34(10): 887

    Google Scholar 

  2. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan–Feb; 12(1): 17–29

    Article  PubMed  Google Scholar 

  3. Ferner RE, Aronson JK. Preventability of drug-related harms —part I: a systematic review. Drug Saf 2010 Nov 1; 33(11): 985–94

    Article  PubMed  Google Scholar 

  4. Aronson JK, Ferner RE. Preventability of drug-related harms —part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010 Nov 1; 33(11): 995–1002

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author has no conflicts of interest, financial or otherwise, that have any bearing on the content of this paper.

Author information

Authors and Affiliations

  1. Uppsala Monitoring Centre, Box 1051, Uppsala, SE 751 40, Sweden

    I. Ralph Edwards

Authors
  1. I. Ralph Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Ralph Edwards.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, I.R. Prevention and Pharmacovigilance. Drug Saf 35, 87–90 (2012). https://doi.org/10.2165/11630510-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11630510-000000000-00000

Search

Navigation